Previous close | 243.27 |
Open | 243.57 |
Bid | 238.47 x 100 |
Ask | 240.20 x 100 |
Day's range | 238.03 - 243.57 |
52-week range | 204.44 - 261.54 |
Volume | |
Avg. volume | 406,550 |
Market cap | 11.247B |
Beta (5Y monthly) | 0.52 |
PE ratio (TTM) | 12.06 |
EPS (TTM) | 19.81 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 292.25 |
Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), sold 30,000 shares of the company on March 26, 2024, according to a recent SEC Filing.
A closer look at one of the leaders in the pulmonary arterial hypertension treatment market
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 26, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled "Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review," in the journal Physiological Reviews. The manuscript is the first detailed overview of the current state of the xenotransplantation industry and, in one place, collects the vast history o